[EN] BRIDGED, BICYCLIC HETEROCYCLIC OR SPIRO BICYCLIC HETEROCYCLIC DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF [FR] DÉRIVÉS HÉTÉROCYCLIQUES BICYCLIQUES PONTÉS OU HÉTÉROCYCLIQUES BICYCLIQUES SPIRO DE PYRAZOLO[1,5-A]PYRIMIDINES, LEURS PROCÉDÉS DE PRÉPARATION ET LEURS UTILISATIONS
[EN] BRIDGED, BICYCLIC HETEROCYCLIC OR SPIRO BICYCLIC HETEROCYCLIC DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF [FR] DÉRIVÉS HÉTÉROCYCLIQUES BICYCLIQUES PONTÉS OU HÉTÉROCYCLIQUES BICYCLIQUES SPIRO DE PYRAZOLO[1,5-A]PYRIMIDINES, LEURS PROCÉDÉS DE PRÉPARATION ET LEURS UTILISATIONS
Novel pyrazolopyrimidines as highly potent B-Raf inhibitors
作者:Martin J. Di Grandi、Dan M. Berger、Darrin W. Hopper、Chunchun Zhang、Minu Dutia、Alejandro L. Dunnick、Nancy Torres、Jeremy I. Levin、George Diamantidis、Christoph W. Zapf、Jonathan D. Bloom、YongBo Hu、Dennis Powell、Donald Wojciechowicz、Karen Collins、Eileen Frommer
DOI:10.1016/j.bmcl.2009.10.058
日期:2009.12
A novel series of pyrazolo[1,5-a]pyrimidines bearing a 3-hydroxyphenyl group at C(3) and substituted tropanes at C(7) have been identified as potent B-Raf inhibitors. Exploration of alternative functional groups as a replacement for the C(3) phenol demonstrated indazole to be an effective isostere. Several compounds possessing substituted indazole residues, such as 4e, 4p, and 4r, potently inhibited
一种新型的吡唑并[1,5- a ]嘧啶在C(3)处带有3-羟基苯基,在C(7)处具有取代的托烷类被确定为有效的B-Raf抑制剂。探索替代的官能团,以取代C(3)酚证明吲唑是有效的等排物。几种具有取代的吲唑残基的化合物(例如4e,4p和4r)在亚微摩尔浓度下可有效抑制A375和WM266细胞系中的细胞增殖,后两种化合物在细胞中也表现出良好的治疗指数。
Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof
申请人:Levin Jeremy Ian
公开号:US20100029657A1
公开(公告)日:2010-02-04
Compounds of formula A:
and pharmaceutically acceptable salts thereof are described, which selectively inhibit Raf kinase activity and are useful for treating disorders mediated by Raf kinases.
Indazolylpyrazolopyrimidine as Highly Potent B-Raf Inhibitors with in Vivo Activity
作者:Xiaolun Wang、Dan M. Berger、Edward J. Salaski、Nancy Torres、Minu Dutia、Cilien Hanna、Yongbo Hu、Jeremy I. Levin、Dennis Powell、Donald Wojciechowicz、Karen Collins、Eileen Frommer、Judy Lucas
DOI:10.1021/jm1007566
日期:2010.11.11
Novel indazolylpyrazolo[1,5-a]pyrimidine analogues have been prepared and found to be extremely potent type I B-Raf inhibitors. The lead compound shows good selectivity against a panel of 60 kinases, possesses a desirable pharmacokinetic profile, and demonstrates excellent in vivo antitumor efficacy in B-Raf mutant xenograft models.
BRIDGED, BICYCLIC HETEROCYCLIC OR SPIRO BICYCLIC HETEROCYCLIC DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF